PDCD1 and neoplasm: Increased expression of SK1 in tumor cells is significantly associated with shorter survival in metastatic melanoma patients treated with anti-PD-1, and targeting SK1 enhances the responses to ICIs in murine models of melanoma, breast and colon cancer with limited Tregs infiltration (160).